| 47.54 -4.33 (-8.35%) | 01-23 10:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 64.47 | 1-year : | 75.3 |
| Resists | First : | 55.2 | Second : | 64.47 |
| Pivot price | 39.42  |
|||
| Supports | First : | 39.04 |
Second : | 29.05 |
| MAs | MA(5) : | 47.05 |
MA(20) : | 37.32 |
| MA(100) : | 28.53 |
MA(250) : | 29.14 |
|
| MACD | MACD : | 4.8 |
Signal : | 3.4 |
| %K %D | K(14,3) : | 87 |
D(3) : | 93.6 |
| RSI | RSI(14): 73 |
|||
| 52-week | High : | 55.2 | Low : | 22.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRNA ] has closed below upper band by 13.4%. Bollinger Bands are 316.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 55.21 - 55.4 | 55.4 - 55.57 |
| Low: | 49.53 - 49.77 | 49.77 - 49.98 |
| Close: | 51.5 - 51.82 | 51.82 - 52.13 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Thu, 22 Jan 2026
Moderna (NASDAQ:MRNA) Trading Up 10.2% - Time to Buy? - MarketBeat
Thu, 22 Jan 2026
Moderna cutting R&D on vaccines amid U.S. pushback: CEO (MRNA) - Seeking Alpha
Thu, 22 Jan 2026
Moderna Stock Explodes To New 52-Week High: What's Driving The Action? - Benzinga
Thu, 22 Jan 2026
Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash - Bloomberg.com
Wed, 21 Jan 2026
mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say - Ars Technica
Wed, 21 Jan 2026
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 391 (M) |
| Shares Float | 364 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 68,320 (K) |
| Shares Short P.Month | 68,080 (K) |
| EPS | -8.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.86 |
| Profit Margin | -139.7 % |
| Operating Margin | -25.6 % |
| Return on Assets (ttm) | -15.5 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | -45.5 % |
| Gross Profit (p.s.) | -6.15 |
| Sales Per Share | 5.7 |
| EBITDA (p.s.) | -8.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,980 (M) |
| Levered Free Cash Flow | -1,980 (M) |
| PE Ratio | -6.06 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 8.54 |
| Price to Cash Flow | -9.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|